A TALEN-based strategy for efficient bi-allelic miRNA ablation in human cells

RNA

Volumn 20, Issue 6, 2014, Pages 948-955

  Uhde Stone, Claudia ^a   Sarkar, Nandita ^b   Antes, Travis ^b   Otoc, Nicole ^b   Kim, Young ^b   Jiang, Yan J ^c   Lu, Biao ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b System Biosciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Double knockout; Gene editing; Homology directed repair (HDR); MicroRNA; Transcription activator like effector nucleases (TALENs)

Indexed keywords

ESTERASE; HYDROLASE; MICRORNA 21; NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; BI ALLELIC MIRNA ABLATION; CELL POPULATION; CELL PROLIFERATION; DOWN REGULATION; GENE; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE ISOLATION; GENE LOCUS; GENE LOSS; GENE TARGETING; GENETIC PROCEDURES; GENOTYPE; HEK293 CELL LINE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN GENOME; KNOCKOUT GENE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TMEM49 GENE; UPREGULATION; WESTERN BLOTTING;

DOUBLE KNOCKOUT; GENE-EDITING; HOMOLOGY-DIRECTED REPAIR (HDR); MICRORNA; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS);

ALLELES; CELL PROLIFERATION; ESTERASES; GENE KNOCKOUT TECHNIQUES; GENE TARGETING; GENETIC VECTORS; GENOME, HUMAN; HEK293 CELLS; HUMANS; MICRORNAS; PILOT PROJECTS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME;

EID: 84901418880     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.042010.113     Document Type: Article

References (54)

1. Amiel J, de Pontual L, Henrion-Caude A. 2012. miRNA, developmentand disease. Adv Genet 80: 1-36.
2. Ansai S, Sakuma T, Yamamoto T, Ariga H, Uemura N, Takahashi R,Kinoshita M. 2013. Efficient targeted mutagenesis in medaka usingcustom-designed transcription activator-like effector nucleases.Genetics 193: 739-749.
3. Bogdanove AJ, Voytas DF. 2011. TAL effectors: customizable proteinsfor DNA targeting. Science 333: 1843-1846.
4. Bollag RJ, Waldman AS, Liskay RM. 1989. Homologous recombinationin mammalian cells. Annu Rev Genet 23: 199-225.
5. Briggs AW, Rios X, Chari R, Yang L, Zhang F, Mali P, Church GM. 2012.Iterative capped assembly: rapid and scalable synthesis of repeatmoduleDNA such as TAL effectors from individual monomers.Nucleic Acids Res 40: e117.
6. Buscaglia LE, Li Y. 2011. Apoptosis and the target genes of microRNA-21. Chin J Cancer 30: 371-380.
7. Carlson DF, Tan W, Lillico SG, Stverakova D, Proudfoot C, Christian M,Voytas DF, Long CR, Whitelaw CB, Fahrenkrug SC. 2012. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci109: 17382-17387.
8. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C,Baller JA, Somia NV, Bogdanove AJ, Voytas DF. 2011. Efficient designand assembly of custom TALEN and other TAL effector-basedconstructs for DNA targeting. Nucleic Acids Res 39: e82.
9. Cho SW, Kim S, Kim JM, Kim JS. 2013. Targeted genome engineering inhuman cells with the Cas9 RNA-guided endonuclease. NatBiotechnol 31: 230-232.
10. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A,Bogdanove AJ, Voytas DF. 2010. Targeting DNA double-strandbreaks with TAL effector nucleases. Genetics 186: 757-761.
11. Clark KJ, Voytas DF, Ekker SC. 2011. A tale of two nucleases: gene targetingfor the masses? Zebrafish 8: 147-149.
12. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X,Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineeringusing CRISPR/Cas systems. Science 339: 819-823.
13. Doyle EL, Booher NJ, Standage DS, Voytas DF, Brendel VP, Vandyk JK,Bogdanove AJ. 2012. TAL Effector-Nucleotide Targeter (TALE-NT)2.0: tools for TAL effector design and target prediction. Nucleic AcidsRes 40: W117-W122.
14. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD.2013. High-frequency off-target mutagenesis induced by CRISPRCasnucleases in human cells. Nat Biotechnol 31: 822-826.
15. Gaj T, Gersbach CA, Barbas CF III. 2013. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397-405.
16. Gommans WM, Berezikov E. 2012. Controlling miRNA regulation indisease. Methods Mol Biol 822: 1-18.
17. Hafez M, Hausner G. 2012. Homing endonucleases: DNA scissors on amission. Genome 55: 553-569.
18. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ,Zhang L, Santiago Y, Miller JC, et al. 2011. Genetic engineering ofhuman pluripotent cells using tale nucleases. Nat Biotechnol 29:731-734.
19. Hu R, Wallace J, Dahlem TJ, Grunwald DJ, O'Connell RM. 2013a.Targeting human microRNA genes using engineered tal-effector nucleases(TALENS). PLoS One 8: e63074.
20. Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S,Benedetto C, Mitidieri M, Katsaros D, et al. 2013b. The heterochronicmicroRNA let-7 inhibits cell motility by regulating the genesin the actin cytoskeleton pathway in breast cancer. Mol Cancer Res11: 240-250.
21. Huang S, Li XQ, Chen X, Che SM, ChenW, Zhang XZ. 2012. Inhibitionof microRNA-21 increases radiosensitivity of esophageal cancer cellsthrough phosphatase and tensin homolog deleted on chromosome10 activation. Dis Esophagus 26: 823-831.
22. Iorio MV, Croce CM. 2012a. MicroRNA dysregulation in cancer: diagnostics,monitoring and therapeutics. A comprehensive review.EMBO Mol Med 4: 143-159.
23. Iorio MV, Croce CM. 2012b. MicroRNA involvement in human cancer.Carcinogenesis 33: 1126-1133.
24. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B,Cavet G, Linsley PS. 2003. Expression profiling reveals off-targetgene regulation by RNAi. Nat Biotechnol 21: 635-637. (Pubitemid 36638089)
25. Joung JK, Sander JD. 2013. TALENS: a widely applicable technology fortargeted genome editing. Nat Rev Mol Cell Biol 14: 49-55.
26. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. 2009.Transfection of small RNAs globally perturbs gene regulation by endogenousmicroRNAs. Nat Biotechnol 27: 549-555.
27. Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, Kim S,Lee C, Jeong E, Chung E, et al. 2013a. A library of TAL effectornucleases spanning the human genome. Nat Biotechnol 31:251-258.
28. Kim YK, Wee G, Park J, Kim J, Baek D, Kim JS, Kim VN. 2013b.TALEN-based knockout library for human microRNAs. Nat StructMol Biol 20: 1458-1464.
29. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M,Stoffel M. 2005. Silencing of microRNAs in vivo with 'antagomirs'.Nature 438: 685-689.
30. Li S, Liang Z, Xu L, Zou F. 2012a. MicroRNA-21: a ubiquitously expressedpro-survival factor in cancer and other diseases. Mol CellBiochem 360: 147-158.
31. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM, Shen ZJ.2012b. miR-21 as an independent biochemical recurrence predictorand potential therapeutic target for prostate cancer. J Urol 187:1466-1472.
32. Liu CZ, Liu W, Zheng Y, Su JM, Li JJ, Yu L, He XD, Chen SS. 2012.PTEN and PDCD4 are bona fide targets of microRNA-21 in humancholangiocarcinoma. Chin Med Sci J 27: 65-72.
33. Liu F, Zheng S, Liu T, Liu Q, Liang M, Li X, Sheyhidin I, Lu X, Liu W.2013. MicroRNA-21 promotes the proliferation and inhibits apoptosisin Eca109 via activating ERK1/2/MAPK pathway. Mol CellBiochem 381: 115-125.
34. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE,Church GM. 2013. RNA-guided human genome engineering viaCas9. Science 339: 823-826.
35. Mendenhall A, Lesnik J, Mukherjee C, Antes T, Sengupta R. 2012.Packaging HIV- or FIV-based lentivector expression constructsand transduction of VSV-G pseudotyped viral particles. J Vis Exp62: e3171.
36. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, et al. 2011. A TALE nuclease architecturefor efficient genome editing. Nat Biotechnol 29: 143-148.
37. Moore FE, Reyon D, Sander JD, Martinez SA, Blackburn JS, Khayter C,Ramirez CL, Joung JK, Langenau DM. 2012. Improved somatic mutagenesisin zebrafish using transcription activator-like effector nucleases(TALENS). PLoS One 7: e37877.
38. Park CY, Choi YS, McManus MT. 2010. Analysis of microRNA knockoutsin mice. Hum Mol Genet 19: R169-R175.
39. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R,Richards H, Li Z, Adler D, Yoshinaga Y, et al. 2012. A resource forthe conditional ablation of microRNAs in the mouse. Cell Rep 1:385-391.
40. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN. 2010. Stress-dependent cardiac remodeling occursin the absence of microRNA-21 in mice. J Clin Invest 120:3912-3916.
41. Pauli A, Rinn JL, Schier AF. 2011. Non-coding RNAs as regulators ofembryogenesis. Nat Rev Genet 12: 136-149.
42. Perez-Pinera P, Ousterout DG, Gersbach CA. 2012. Advances in targetedgenome editing. Curr Opin Chem Biol 16: 268-277.
43. Rahman SH, Maeder ML, Joung JK, Cathomen T. 2011. Zinc-finger nucleasesfor somatic gene therapy: the next frontier. Hum Gene Ther22: 925-933.
44. Sakuma T, Hosoi S, Woltjen K, Suzuki K, Kashiwagi K, Wada H,Ochiai H, Miyamoto T, Kawai N, Sasakura Y, et al. 2013. EfficientTALEN construction and evaluation methods for human cell andanimal applications. Genes Cells 18: 315-326.
45. Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. 2012. Atranscription activator-like effector toolbox for genome engineering.Nat Protoc 7: 171-192.
46. Sun N, Zhao H. 2013. Transcription activator-like effector nucleases(TALENS): a highly efficient and versatile tool for genome editing.Biotechnol Bioeng 110: 1811-1821.
47. Sung YH, Baek IJ, Kim DH, Jeon J, Lee J, Lee K, Jeong D, Kim JS,Lee HW. 2013. Knockout mice created by TALEN-mediated genetargeting. Nat Biotechnol 31: 23-24.
48. Svoboda P, Flemr M. 2010. The role of miRNAs and endogenoussiRNAs in maternal-to-zygotic reprogramming and the establishmentof pluripotency. EMBO Rep 11: 590-597.
49. Tong C, Huang G, Ashton C, Wu H, Yan H, Ying QL. 2012. Rapid andcost-effective gene targeting in rat embryonic stem cells by TALENS.J Genet Genomics 39: 275-280.
50. Uhde-Stone C, Gor N, Chin T, Huang J, Lu B. 2013. A do-it- yourselfprotocol for simple transcription activator-like effector assembly.Biol Proced Online 15: 3.
51. van Dongen S, Abreu-Goodger C, Enright AJ. 2008. Detecting micro-RNA binding and siRNA off-target effects from expression data.Nat Methods 5: 1023-1025.
52. Xu WD, Pan HF, Li JH, Ye DQ. 2013. MicroRNA-21 with therapeuticpotential in autoimmune diseases. Expert Opin Ther Targets 17:659-665.
53. Zhang Y, Zhang F, Li X, Baller JA, Qi Y, Starker CG, Bogdanove AJ,Voytas DF. 2013. Transcription activator-like effector nucleases enableefficient plant genome engineering. Plant Physiol 161: 20-27.
54. Zhu Q, Sun W, Okano K, Chen Y, Zhang N, Maeda T, Palczewski K.2011. Sponge transgenic mouse model reveals important roles forthe microRNA-183 (mir-183)/96/182 cluster in postmitotic photoreceptorsof the retina. J Biol Chem 286: 31749-31760.